Mike Taylor (@herrison) 's Twitter Profile
Mike Taylor

@herrison

Victory to Ukraine

ID: 14711619

linkhttp://www.111theatre.co.uk calendar_today09-05-2008 09:47:17

3,3K Tweet

1,1K Takipçi

736 Takip Edilen

Mike Taylor (@herrison) 's Twitter Profile Photo

Always a great privilege to co-author with colleagues from pharma - I don't have a PDF to share yet, but I will do - tandfonline.com/doi/full/10.10…

Mike Taylor (@herrison) 's Twitter Profile Photo

Once again, I find myself talking about the Earl of Balcarres, and his post-mortum, as published in 1665: an example of celebrities attracting attention in science - doi.org/10.1098/rstl.1…

Mork Jenkinsnot's ghost (@mp_mork) 's Twitter Profile Photo

Liz Truss is an absolute inspiration to me. Becoming Prime Minister, despite her complete lack of any understanding of anything at all, gives half wits like me the confidence to persevere.

Liz Truss is an absolute inspiration to me.  Becoming Prime Minister, despite her complete lack of any understanding of anything at all,  gives half wits like me the confidence to persevere.
Marcelo Corassa, MD. (@marcelocorassa) 's Twitter Profile Photo

So, 5y PFS is out. CROWN shows that only 3% of patients had disease progression from year 4 to year 5. Toxic, Lorlatinib is indeed, but this in totally unprecedented in thoracic oncology. ALK fusion patients leading the way into making NSCLC a chronic disease #ASCO24

So, 5y PFS is out. CROWN shows that only 3% of patients had disease progression from year 4 to year 5. Toxic, Lorlatinib is indeed, but this in totally unprecedented in thoracic oncology. ALK fusion patients leading the way into making NSCLC a chronic disease #ASCO24
Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

So which ALK inhibitor is best in class ? Who gets the CROWN at the 5 years follow up ? Lorlatinib vs Crizotinib. Lorlatinib PFS HR 0.24 for pts without Brain mets . Median PFS not reached . HR of 0.08 for those with brain mets . Clearly Lorlatinib is winner . ASCO #ASCO24

So which ALK inhibitor is best in class ? Who gets the CROWN at the 5 years follow up ? Lorlatinib vs Crizotinib.  Lorlatinib PFS HR 0.24 for pts without Brain mets .  Median PFS not reached . HR of 0.08 for those with brain mets .  Clearly Lorlatinib is winner . <a href="/ASCO/">ASCO</a> #ASCO24
Mike Taylor (@herrison) 's Twitter Profile Photo

The grief I get for having mildly entertaining titles for my research, and then this... pearl turns up link.springer.com/article/10.100…

Mike Taylor (@herrison) 's Twitter Profile Photo

Since I'm writing the follow-up paper, thought I ought to post the last one :) while I wait (and wait) on peer review arxiv.org/abs/2406.10535 Turns out the #oa advantage is super complex (stay tuned for a second paper this summer)

Mike Taylor (@herrison) 's Twitter Profile Photo

Ground breaking study that continues to show that using celebrities as case studies and subjects boosts public engagement with research Carlos Areia taylorfrancis.com/chapters/edit/…

Digital Science (@digitalsci) 's Twitter Profile Photo

Hear Digital Science's Head of Data Insights, Mike Taylor (Mike Taylor), in this new podcast hosted by MAPS: "Maximizing the Impact of a Niche Publication". 🔊 Listen to the podcast or see a transcript: ow.ly/TtuW50SP2wK Altmetric #MedAffairs #MedicalAffairs

Hear <a href="/digitalsci/">Digital Science</a>'s Head of Data Insights, Mike Taylor (<a href="/herrison/">Mike Taylor</a>), in this new podcast hosted by <a href="/MAPSmedaffairs/">MAPS</a>: "Maximizing the Impact of a Niche Publication".

🔊 Listen to the podcast or see a transcript: ow.ly/TtuW50SP2wK

<a href="/altmetric/">Altmetric</a> #MedAffairs #MedicalAffairs
Mike Taylor (@herrison) 's Twitter Profile Photo

I am continuing to be proud of supporting APOPO and urge people to check out doi.org/10.1186/s12879… Rats are amazingly fast and accurate when it comes to diagnosing TB